The injury happened once. The inflammation, the oxygen debt, the fog — that keeps happening. Months or years later, the brain is still running on a reduced supply.
Acute TBI gets emergency medicine — imaging, surgery if needed, ICP management. After that, the options thin out fast. Rehabilitation focuses on compensatory strategies: speech therapy, occupational therapy, cognitive exercises. Pharmaceuticals target symptoms individually — stimulants for attention, SSRIs for mood, anticonvulsants for seizures. There is no approved drug that repairs injured brain tissue or restores lost perfusion. Most patients plateau within 6–12 months and are told this is their new baseline.
Boussi-Gross et al. (2013) conducted a prospective crossover trial in PLOS ONE with 56 post-TBI patients (1–5 years post-injury) receiving 40 sessions at 1.5 ATA. SPECT imaging showed significant increases in brain perfusion, and patients demonstrated measurable gains in memory, attention, and executive function — well past the accepted recovery window.1
Tal et al. (2015) published in PLOS ONE a study of mild TBI patients treated at 1.5 ATA for 60 sessions. Results showed restored cognitive function and improved quality of life, with SPECT imaging confirming increased activity in previously damaged regions. The improvements correlated with objective perfusion changes, not just subjective reporting.2
Harch et al. (2012) treated 16 military service members with persistent post-concussion syndrome at 1.5 ATA in a study published in the Journal of Neurotrauma. After 40 sessions, participants showed significant improvements in symptoms, cognitive testing, and SPECT perfusion. Full-scale IQ increased by an average of 14.8 points.3
Efrati et al. (2013) demonstrated in PLOS ONE that HBOT at 1.5 ATA could induce neuroplasticity in chronic stroke patients — a closely related ischemic brain injury — even years after the initial event, confirming that the brain retains the capacity for oxygen-driven repair far beyond conventional timelines.4
Naeser et al. (2014) published in Photomedicine and Laser Surgery a case series of chronic TBI patients treated with transcranial LED therapy at 810 nm and 633 nm. Patients showed improved executive function, verbal memory, and sleep after 18 sessions, with effects sustained at follow-up. The proposed mechanism was enhanced mitochondrial function via cytochrome c oxidase.5
Hamblin (2018) reviewed the TBI photobiomodulation literature in BBA Clinical, summarizing evidence that near-infrared light at 810 nm penetrates the skull sufficiently to reduce neuroinflammation, promote neurogenesis, and increase cerebral blood flow. Animal models showed reduced lesion size and improved behavioral outcomes when treatment began even days post-injury.6
Figueiro Longo et al. (2020) published a randomized, sham-controlled trial in JAMA Network Open showing that transcranial photobiomodulation improved cognitive function in patients with chronic TBI, with significant gains on the Rivermead Post-Concussion Symptoms Questionnaire compared to sham.7